About Dr Ellie Rashid
Consultant Dermatologist
Skin Health & Allergy
Sub-specialties: Paediatric Dermatology, Hidradenitis Suppurativa, Mole Checks, Acne, Rosacea, Eczema, Psoriasis, Pigmentation Disorders, Vitiligo, Melasma, Dermatology, General Dermatology, Biologics.
Dr Ellie Rashid consults on all aspects of dermatology including paediatric dermatology, hidradenitis suppurativa, mole checks, acne, rosacea, eczema, psoriasis, pigmentation disorders, vitiligo and melasma. She is joint training program director for specialist dermatology training in London.
Bookings: Tel: 
Dr Ellie Rashid consults on all aspects of dermatology including paediatric dermatology, hidradenitis suppurativa, mole checks, acne, rosacea, eczema, psoriasis, pigmentation disorders, vitiligo and melasma. She is joint training program director for specialist dermatology training in London.
Areas of Expertise
Ellie Rashid performs a range of treatments including:
- General Dermatology
- Paediatric Dermatology
- Hidradenitis Suppurativa
Some of the conditions she commonly treats are:
- Psoriasis
- Acne
- Melasma
- Eczema
- Rosacea
- Mole checks
- Biologics
About Dr Ellie Rashid
Dr Ellie Rashid is a Consultant Dermatologist at OneWelbeck Skin Health and Allergy and Clinical Lead for the complex Hidradenitis Suppurativa tertiary service at St John’s Institute of Dermatology. She consults on all aspects of dermatology including paediatric dermatology, hidradenitis suppurativa, mole checks, acne, rosacea, eczema, psoriasis, pigmentation disorders, vitiligo and melasma. She is joint training program director for specialist dermatology training in London.
She is an Honorary Senior Lecturer at King’s College London. She graduated from Bart’s and the London Medical School in 2006 and completed her rigorous dermatology specialist registrar training at St. John’s Institute of Dermatology. She was awarded a PhD in Stem Cells and Regenerative Medicine in 2021.
She continues to publish original research in peer reviewed journals, and written textbook chapters on dermatology. She has presented at international scientific meetings globally and has been awarded numerous awards for her clinical activity and research including the Hugh Wallace award, European Society for Investigative Dermatology award and the La Roche-Posay research award for Europe.
Additional Information
Awards
- 2021 – La Roche-Posay Research Award Publication Prize for Europe for publication of Open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa
- 2018 – European Society for Investigative Dermatology travel award
- 2015 – British Society of Paediatrics award for best presentation – British Association of Dermatology
- 2015 – Hugh Wallace prize for best publication – Royal Society of Medicine
- 2015 – British Association of Dermatology/Dowling Club travel fellowship award
- 2013 – St John’s Dermatological Society prize for best presentation
Memberships
- British Association of Dermatologists
- Royal College of Physicians, London
- St John’s Dermatological Society
- London Specialist Training Committee (Training Program Director)
Qualifications
- 2021 – Doctor of Philosophy (PhD) in Stem Cells and Regenerative Medicine, King’s College London
- 2018 – Certificate of Completion of Training (CCT) in dermatology (London)
- 2017 – MRCP (Dermatology)
- 2014 – Postgraduate Certificate in Healthcare Education, St George’s University
- 2011 – Membership of the Royal College of Physicians (MRCP UK)
Research Highlights
Dr Ellie Rashid has achieved multiple publications in peer-reviewed journals.
Key Publications
- Honap S, Meade S, Spencer A, Pavlidis P, Luber RP, Calonje E, Rashidghamat E, Bunker CB, Lewis F, Irving PM. Anogenital Crohn’s Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations and Treatment. J Crohns Colitis. 2021 Nov 20:jjab211. doi: 10.1093
- Robson A, Bakr F, Rashidghamat E, Willsmore Z, Ally M, Greenblatt D, Barlow R, Wain ME, Child F, Esdaile B, Kempf W. Follicular T-helper cells in marginal zone lymphoma: Evidence of an organoid immune response. Am J Dermatopathol. 2021, doi: 10.1097
- Rashidghamat E, Kadiyirire T, Ayis S et al. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2020, 2:447-454
- Rashidghamat E, Mellerio JE. Management of chronic wounds in patients with dystrophic epidermolysis bullosa: challenges and solutions. Chronic wound care management and research. 2017; 4:45-54
- Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017; 1:6-20